Cargando…

Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach

Rifaximin, with its low systemic absorption, may represent a treatment of choice for irritable bowel syndrome (IBS), mainly due to its ability to act on IBS pathogenesis, through the influence on gut microbiota. The aim of the present study was to assess, by biomolecular tools, the rifaximin active...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soldi, Sara, Vasileiadis, Sotirios, Uggeri, Francesca, Campanale, Mariachiara, Morelli, Lorenzo, Fogli, Maria Vittoria, Calanni, Fiorella, Grimaldi, Maria, Gasbarrini, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675645/ https://www.ncbi.nlm.nih.gov/pubmed/26673000 http://dx.doi.org/10.2147/CEG.S89999

Ejemplares similares

Rifaximin Therapy of Irritable Bowel Syndrome
por: Koo, Hoonmo L., et al.
Publicado: (2012)

Profile of rifaximin and its potential in the treatment of irritable bowel syndrome
por: Iorio, Natalya, et al.
Publicado: (2015)

Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea
por: Lembo, Anthony, et al.
Publicado: (2020)

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials
por: Schoenfeld, P., et al.
Publicado: (2014)

Functional constipation masked as irritable bowel syndrome
por: Tosto, Monica, et al.
Publicado: (2020)

High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome
por: Jolley, John
Publicado: (2011)

Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome
por: Boltin, Doron, et al.
Publicado: (2014)

Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome
por: Fodor, Anthony A., et al.
Publicado: (2018)

Optimal management of constipation associated with irritable bowel syndrome
por: Furnari, Manuele, et al.
Publicado: (2015)

Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation
por: Ponziani, Francesca Romana, et al.
Publicado: (2017)

Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials
por: Li, Jun, et al.
Publicado: (2016)

Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin
por: Chang, Christopher
Publicado: (2018)

Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum Metabolites
por: Luo, Mei, et al.
Publicado: (2023)

Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome
por: Zeber-Lubecka, Natalia, et al.
Publicado: (2016)

Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation
por: Eswaran, Shanti, et al.
Publicado: (2014)

Review of Treatment Options for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation
por: Patel, Sarah, et al.
Publicado: (2021)

Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile
por: Gupta, Kamesh, et al.
Publicado: (2017)

Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity
por: Pimentel, M., et al.
Publicado: (2017)

Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome
por: Acosta, Andrés, et al.
Publicado: (2016)

Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea
por: Rezaie, Ali, et al.
Publicado: (2019)

Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review
por: Chey, William D., et al.
Publicado: (2020)

Food Additives, Gut Microbiota, and Irritable Bowel Syndrome: A Hidden Track
por: Rinninella, Emanuele, et al.
Publicado: (2020)

Constipation-Predominant Irritable Bowel Syndrome Associated to Hyperprolactinemia
por: Seretis, C., et al.
Publicado: (2011)

Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3
por: Vicari, Enzo, et al.
Publicado: (2014)

The human intestinal microbiota of constipated-predominant irritable bowel syndrome patients exhibits anti-inflammatory properties
por: Gobert, Alain P., et al.
Publicado: (2016)

Lubiprostone for the Treatment of Adult Women with Irritable Bowel Syndrome with Constipation
por: Soubra, Mahmoud, et al.
Publicado: (2012)

Review article: linaclotide for the management of irritable bowel syndrome with constipation
por: Layer, P, et al.
Publicado: (2014)

White Matter Microstructural Similarity and Diversity of Functional Constipation and Constipation-predominant Irritable Bowel Syndrome
por: Nan, Jiaofen, et al.
Publicado: (2018)

Determination of Rifaximin Treatment Period According to Lactulose Breath Test Values in Nonconstipated Irritable Bowel Syndrome Subjects
por: Bae, Suhyun, et al.
Publicado: (2015)

Does rifaximin offer any promise in Crohn's disease in remission and concurrent irritable bowel syndrome-like symptoms?
por: Tocia, Cristina, et al.
Publicado: (2021)

Effectiveness of Rifaximin on the Outcomes of Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Khan, Zarghuna, et al.
Publicado: (2023)

The Role of Food in the Treatment of Bowel Disorders: Focus on Irritable Bowel Syndrome and Functional Constipation
por: Singh, Prashant, et al.
Publicado: (2022)

Linaclotide: A New Option for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation in Adults
por: Parker, Colleen H., et al.
Publicado: (2013)

Functional Constipation and Constipation-Predominant Irritable Bowel Syndrome in the General Population: Data from the GECCO Study
por: Enck, Paul, et al.
Publicado: (2016)

Rifaximin, Microbiota Biology, and Hepatic Encephalopathy
por: Peleman, Cedric, et al.
Publicado: (2016)

Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom
por: Layer, Peter, et al.
Publicado: (2007)

Saccharomyces cerevisiae I-3856 in irritable bowel syndrome with predominant constipation
por: Mourey, Florian, et al.
Publicado: (2022)

Stem Cell-Based Therapies for Liver Diseases: State of the Art and New Perspectives
por: Piscaglia, Anna Chiara, et al.
Publicado: (2010)

Constipation-Predominant Irritable Bowel Syndrome (IBS-C): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms
por: Di Rosa, Claudia, et al.
Publicado: (2023)

Colonic response to laxative ingestion as assessed by MRI differs in constipated irritable bowel syndrome compared to functional constipation
por: Lam, C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1ftlc19hlfglkmcha94rvjc3ao